Angiotensin 1/2 (2-7)
(Synonyms: H2N-Arg-Val-Tyr-Ile-His-Pro-OH ) 目录号 : GP10045
Vasoconstrictor
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Angiotensin I/II (2-7) is a peptide (ARG-VAL-TYR-ILE-HIS-PRO) that contains the amino acids 2-7 and is converted from Angiotensin I/II peptide.
Angiotensin I is formed by the action of renin on angiotensinogen, an ǁ-2-globulin with 12 amino acids. Angiotensinogen is produced constitutively and released into the circulation mainly by the liver. Renin cleaves the peptide bond between the leucine (Leu) and valine (Val) residues on angiotensinogen, creating the ten-amino acid peptide angiotensin I. Angiotensin I is converted to angiotensin II (AII) through removal of two C-terminal residues by angiotensin-converting enzyme (ACE), primarily by ACE within the lung.
Angiotensin is a peptide hormone that causes vasoconstriction and a subsequent increase in blood pressure. Angiotensin also stimulates the release of aldosterone, which promotes sodium retention in the distal nephron, thereby increasing blood pressure.
References:
1. Basso N, Terragno NA (December 2001). "History about the discovery of the renin-angiotensin system". Hypertension 38 (6): 1246-9.
2. Richard A. Preston. et. (1998). pAge-Race Subgroup Compared With Renin Profile as Predictors of Blood Pressure Response to Antihypertensive Therapyq. JAMA. 1998;280(13):1168-1172.
3. Williams GH, Dluhy RG (2008). "Chapter 336: Disorders of the Adrenal Cortex". In Loscalzo J, Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL. Harrison's principles of internal medicine. McGraw-Hill Medical.
| Cas No. | SDF | ||
| 别名 | H2N-Arg-Val-Tyr-Ile-His-Pro-OH | ||
| Canonical SMILES | N[C@@H](CCCNC(N)=N)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=C(O)C=C1)C(N[C@@H]([C@H](C)CC)C(N[C@@H](CC2=CNC=N2)C(N3CCC[C@@H]3C(O)=O)=O)=O)=O)=O)=O | ||
| 分子式 | C37H57N11O8 | 分子量 | 783.92 |
| 溶解度 | ≥ 78.4mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2756 mL | 6.3782 mL | 12.7564 mL |
| 5 mM | 0.2551 mL | 1.2756 mL | 2.5513 mL |
| 10 mM | 0.1276 mL | 0.6378 mL | 1.2756 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet